Retina

A patient has undergone a premium refractive cataract procedure, and they’re unhappy. How are you going to fix it?

Vaccination complications as an explanation for retinal hemorrhage in children should not be accepted clinically or legally, new study data suggests

Vasotide, a small molecule that stops VEGF binding to endothelial receptor molecules, has shown promise in animal models and can be delivered using eyedrops

U.K. Ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country.

Anti-VEGF monotherapy may not be adequate for all your wet AMD patients. The Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD, intended as a one-time treatment, has been shown to maintain vision while reducing the number of anti-VEGF injections, providing a viable option for patients with significant fluid in the macula.

Christopher Brand, Consultant Ophthalmic Surgeon, discusses the treatment of recently diagnosed wet AMD patients

Professor Dr. Salvatore Grisanti reviews selection criteria for best outcomes using Oraya Therapy for wet AMD

Dr. med Katja Hatz discusses the treat and extend approach to wet AMD with the Oraya Therapy

Consultant ophthalmic surgeon Professor Tariq Aslam shares clinical insights and patient experiences with the Oraya Therapy for the treatment of wet AMD in the UK

Professor Ian Rennie, Consultant Ophthalmologist and International Expert in Treatments of Ocular Cancers, discusses the safe use of radiotherapy for the treatment of wet AMD